Your browser is no longer supported. Please, upgrade your browser.
Settings
XLRN Acceleron Pharma Inc. daily Stock Chart
XLRN [NASD]
Acceleron Pharma Inc.
Index- P/E- EPS (ttm)-2.47 Insider Own1.00% Shs Outstand45.24M Perf Week8.88%
Market Cap2.56B Forward P/E- EPS next Y-2.10 Insider Trans-10.31% Shs Float39.26M Perf Month17.08%
Income-108.50M PEG- EPS next Q-0.65 Inst Own90.90% Short Float10.12% Perf Quarter51.62%
Sales13.60M P/S188.48 EPS this Y-76.20% Inst Trans2.15% Short Ratio8.45 Perf Half Y43.84%
Book/sh7.27 P/B7.79 EPS next Y24.30% ROA-29.10% Target Price57.09 Perf Year61.65%
Cash/sh6.36 P/C8.90 EPS next 5Y- ROE-30.80% 52W Range32.53 - 59.57 Perf YTD33.51%
Dividend- P/FCF- EPS past 5Y35.90% ROI-30.10% 52W High-4.89% Beta1.40
Dividend %- Quick Ratio20.50 Sales past 5Y-2.40% Gross Margin- 52W Low74.18% ATR2.18
Employees139 Current Ratio20.50 Sales Q/Q19.40% Oper. Margin- RSI (14)67.93 Volatility5.84% 3.97%
OptionableYes Debt/Eq0.00 EPS Q/Q17.70% Profit Margin- Rel Volume2.20 Prev Close58.47
ShortableYes LT Debt/Eq0.00 EarningsAug 02 AMC Payout- Avg Volume470.01K Price56.66
Recom2.20 SMA208.63% SMA5017.03% SMA20035.41% Volume1,035,424 Change-3.10%
Sep-10-18Resumed Morgan Stanley Equal-Weight $55
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-10-18Downgrade Piper Jaffray Overweight → Neutral
Jun-29-18Upgrade Goldman Sell → Neutral
Feb-28-18Reiterated Barclays Overweight $50 → $54
Feb-26-18Upgrade JP Morgan Neutral → Overweight
Jan-18-18Resumed Credit Suisse Outperform $55
Nov-07-17Reiterated H.C. Wainwright Buy $57 → $62
Oct-12-17Initiated H.C. Wainwright Buy $57
Sep-15-17Initiated RBC Capital Mkts Sector Perform $44
Jun-13-17Downgrade Oppenheimer Outperform → Perform
May-17-17Initiated Goldman Sell $20
Mar-14-17Initiated JP Morgan Neutral
Mar-09-17Initiated UBS Buy $36
Mar-02-17Upgrade Citigroup Neutral → Buy
Mar-02-17Initiated Instinet Buy $58
Dec-13-16Initiated Oppenheimer Outperform
Sep-29-16Initiated Citigroup Neutral $40
Apr-27-16Initiated Barclays Overweight $40
Feb-01-16Resumed Oppenheimer Outperform
Sep-20-18 08:00AM  Today's Research Reports on Trending Tickers: Acceleron Pharma and Tesaro ACCESSWIRE
Sep-18-18 02:44PM  Analyst: Acceleron's Blood Disorder Candidate Luspatercept Has Blockbuster Potential Benzinga
Sep-04-18 03:17PM  Here's Why Acceleron Pharma Rose 24% in August Motley Fool
Aug-14-18 07:34PM  Edited Transcript of XLRN earnings conference call or presentation 2-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Aug-08-18 04:17PM  Could Biotech Giant Celgene Join Tesla In The Private Markets? Investor's Business Daily
Aug-04-18 01:11PM  Here's Why Acceleron Pharma Inc. Lost 10.2% in July Motley Fool
Aug-03-18 07:52AM  The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings Benzinga
Aug-02-18 06:25PM  Acceleron Pharma (XLRN) Reports Q2 Loss, Tops Revenue Estimates Zacks
05:21PM  Acceleron: 2Q Earnings Snapshot Associated Press
04:05PM  Acceleron Reports Second Quarter 2018 Operating and Financial Results Business Wire
07:53AM  Acceleron Pharma Q2 Earnings Preview Benzinga
Jul-26-18 07:00AM  Acceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018 Business Wire
Jul-18-18 07:15AM  Free Pre-Market Technical Recap on Genesis Healthcare and Three Additional Healthcare Stocks ACCESSWIRE
Jul-13-18 12:45PM  Morgan Stanley Downgrades Acceleron As Valuation Reaches Price Target Benzinga
Jul-12-18 07:00AM  Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy Business Wire
Jul-11-18 09:41AM  Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More Zacks
Jul-10-18 02:50PM  Celgene, Acceleron Report Positive Data on Thalassemia Drug Zacks
11:52AM  Upbeat Celgene Data Not Enough to Lift Biotech Sector Barrons.com
08:11AM  Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage Benzinga
Jul-09-18 06:13PM  [$$] Celgene, Acceleron Say Trial on Blood-Disorder Drug Yields Positive Results The Wall Street Journal
05:13PM  Celgene, Acceleron shares rise on blood-disorder drug study MarketWatch
04:52PM  Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III BELIEVE Study in Adults with Transfusion-Dependent Beta-Thalassemia Business Wire
Jul-05-18 04:30PM  Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer Business Wire
Jul-02-18 08:10AM  Today's Research Reports on Stocks to Watch: Acceleron Pharma and Vertex Pharmaceuticals ACCESSWIRE
Jun-30-18 07:17AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
07:16AM  Celgene Investors Breathe a Sigh of Relief After Acceleron's Success Motley Fool
Jun-29-18 05:00PM  Acceleron Pharma Soars On Celgene-Partnered Anemia Treatment Investor's Business Daily +42.79%
02:54PM  Celgene's Luspatercept Meets Primary Endpoint in the Study Zacks
12:07PM  A Huge Win Sends Acceleron Pharma Shares Soaring 42% Motley Fool
11:10AM  Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn't Buying Benzinga
08:11AM  Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos Benzinga
Jun-28-18 04:30PM  Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III MEDALIST Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes Business Wire
Jun-26-18 07:00AM  Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society Business Wire
Jun-22-18 07:30AM  Market Trends Toward New Normal in RCI Hospitality, Phillips 66 Partners LP, Acceleron Pharma, Destination Maternity, The RMR Group, and Cohen & Steers Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jun-15-18 07:00AM  Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association Business Wire
Jun-08-18 05:01PM  Big News Is Fast Approaching for Celgene Motley Fool
Jun-06-18 02:07PM  Edited Transcript of XLRN earnings conference call or presentation 8-May-18 9:00pm GMT Thomson Reuters StreetEvents
Jun-04-18 07:00AM  Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting Business Wire
May-24-18 07:20AM  Wired News Acceleron Pharma Commences PULSAR Phase-2 Trial of Sotatercept in Pulmonary Arterial Hypertension ACCESSWIRE
May-22-18 07:00AM  Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension Business Wire
May-17-18 09:21AM  Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association Business Wire
May-08-18 05:11PM  Acceleron: 1Q Earnings Snapshot Associated Press
04:01PM  Acceleron Reports First Quarter 2018 Operating and Financial Results Business Wire
May-03-18 07:55AM  Factors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture, Senseonics, Acceleron Pharma, and Steelcase New Research Emphasizes Economic Growth GlobeNewswire
May-02-18 11:56AM  Boston biotech entrepreneur Christoph Westphal launches new startup American City Business Journals
07:00AM  Acceleron to Participate in Two Healthcare Investor Conferences in May Business Wire
May-01-18 07:00AM  Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD) Business Wire
Apr-30-18 07:00AM  Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018 Business Wire -7.50%
Apr-26-18 08:00AM  Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting Business Wire
07:00AM  Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting Business Wire
Apr-22-18 07:15AM  2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line Motley Fool
Mar-20-18 08:30AM  Report: Developing Opportunities within Heico, Global Medical REIT, Acceleron Pharma, Momenta Pharmaceuticals, Silgan, and Weingarten Realty Investors Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-12-18 07:00AM  Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial Business Wire
Mar-06-18 11:02AM  High Growth NasdaqGM Stocks For The Day Simply Wall St.
Feb-28-18 06:11PM  Edited Transcript of XLRN earnings conference call or presentation 27-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
07:04AM  Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve Business Wire
Feb-27-18 07:17PM  Acceleron reports 4Q loss Associated Press
04:05PM  Acceleron Reports Fourth Quarter and Full Year 2017 Operating and Financial Results Business Wire
01:00PM  Acceleron Pharma Inc to Host Earnings Call ACCESSWIRE
Feb-20-18 07:00AM  Acceleron to Webcast Fourth Quarter and Full Year 2017 Operating and Financial Results on February 27, 2018 Business Wire
Feb-08-18 04:01PM  Acceleron Announces Appointment of Chief Commercial Officer Business Wire -6.93%
Jan-31-18 07:00AM  Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference Business Wire
Jan-23-18 08:00AM  Celgene's Investments Are Soaring Motley Fool
Jan-17-18 08:20AM  Consolidated Research: 2018 Summary Expectations for Eclipse Resources, Unit, Post, Acceleron Pharma, SELECT EGY SVCS, and Concho Resources Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-08-18 11:05AM  Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy Business Wire
Jan-03-18 07:00AM  Acceleron Announces Planned Retirement of Chief Medical Officer, Dr. Matthew L. Sherman Business Wire
Jan-02-18 07:00AM  Acceleron to Webcast Presentation at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-22-17 03:00AM  Acceleron Pharma Joins Rank Of Stocks With RS Ratings Over 90 Investor's Business Daily
Dec-21-17 03:00AM  Acceleron Pharma Hits 80-Plus Relative Strength Rating Benchmark Investor's Business Daily +9.00%
Dec-19-17 03:00AM  Stocks Showing Improved Relative Strength: Acceleron Pharma Investor's Business Daily
Dec-14-17 07:30AM  Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : December 14, 2017 Capital Cube
Dec-12-17 03:00AM  Acceleron Pharma Sees RS Rating Climb To 74 Investor's Business Daily
Dec-10-17 09:00AM  Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology Business Wire
Dec-07-17 04:28PM  5 Health Care Stocks Gurus Are Buying GuruFocus.com
Dec-05-17 07:00AM  Acceleron to Host Conference Call and Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meeting and Exposition Business Wire
Nov-20-17 07:26AM  Acceleron Pharma, Inc. breached its 50 day moving average in a Bullish Manner : XLRN-US : November 20, 2017 Capital Cube
Nov-16-17 07:10AM  Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195 ACCESSWIRE
Nov-15-17 04:01PM  Acceleron Announces Appointment of Dr. Karen Smith to its Board of Directors and Departure of Terrance McGuire Business Wire
Nov-14-17 04:01PM  Acceleron Announces Preclinical Results in Pulmonary Arterial Hypertension at the American Heart Association 2017 Scientific Sessions Business Wire
Nov-09-17 10:46PM  Edited Transcript of XLRN earnings conference call or presentation 7-Nov-17 1:00pm GMT Thomson Reuters StreetEvents
01:23PM  ETFs with exposure to Acceleron Pharma, Inc. : November 9, 2017 Capital Cube
Nov-08-17 02:38PM  Acceleron Pharma, Inc. :XLRN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 Capital Cube
Nov-07-17 07:15AM  Acceleron reports 3Q loss Associated Press -5.63%
07:00AM  Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results Business Wire
Nov-06-17 01:23PM  Acceleron Pharma, Inc. Value Analysis (NASDAQ:XLRN) : November 6, 2017 Capital Cube
Nov-03-17 08:36AM  Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : November 3, 2017 Capital Cube
Nov-01-17 09:19AM  Acceleron to Present Clinical Presentations at the 59th American Society of Hematology Annual Meeting and Exposition Business Wire
Oct-26-17 07:00AM  Acceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017 Business Wire
Oct-25-17 12:34PM  Edited Transcript of XLRN earnings conference call or presentation 8-May-17 12:00pm GMT Thomson Reuters StreetEvents
Oct-23-17 08:32AM  Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : October 23, 2017 Capital Cube
Oct-18-17 08:36AM  Options Traders Expect Huge Moves in Acceleron Pharma (XLRN) Stock Zacks
Oct-12-17 03:32PM  4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate Benzinga
Oct-05-17 07:00AM  Acceleron Announces Closing of Underwriters Option to Purchase Additional Shares Business Wire
Oct-02-17 08:10AM  Today's Research Reports on Stocks to Watch: Celgene Corporation and Acceleron Pharma ACCESSWIRE
Sep-29-17 05:50AM  [$$] Celgene Invests in Acceleron, BeiGene Barrons.com
03:00AM  Stocks Flashing Renewed Technical Strength: Acceleron Pharma Investor's Business Daily
Sep-27-17 03:00AM  Acceleron Pharma Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
Sep-26-17 03:00AM  Acceleron Pharma Trying To Close In On Key Technical Measure Investor's Business Daily
Sep-25-17 08:19AM  Acceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : September 25, 2017 Capital Cube
Sep-21-17 10:27AM  What Is Acceleron Pharma Incs (XLRN) Share Price Doing? Simply Wall St. -7.10%
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerAug 30Option Exercise27.9712,500349,62556,439Aug 31 07:00 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerAug 30Sale54.0012,500675,00043,939Aug 31 07:00 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJun 29Option Exercise24.1125,000602,75068,939Jul 03 02:32 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJun 29Sale48.0025,0001,200,00043,939Jul 03 02:32 PM
Rovaldi ChristopherSVP, Program Mgmt and OpsApr 03Sale38.403,500134,39525,858Apr 04 04:41 PM
Quisel John DSVP, Corp. Dev., GC & Sec.Apr 03Sale38.401,20446,23256,598Apr 04 04:40 PM
Kumar RavindraSVP & Chief Scientific OfficerApr 03Sale38.411,20346,20595,935Apr 04 04:40 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 03Sale38.454,000153,79243,939Apr 04 04:38 PM
Sherman Matthew LEVP & Chief Medical OfficerApr 03Sale38.434,600176,77268,767Apr 04 04:39 PM
Maniatis TomDirectorMar 21Option Exercise5.0818,75095,250135,481Mar 23 05:48 PM
POPS RICHARD FDirectorMar 06Option Exercise5.0837,500190,50068,750Mar 08 04:11 PM
POPS RICHARD FDirectorMar 06Sale41.4237,5001,553,09431,250Mar 08 04:11 PM
Rovaldi ChristopherSVP, Program Mgmt and OpsJan 12Option Exercise24.1111,000265,21035,701Jan 17 05:14 PM
Rovaldi ChristopherSVP, Program Mgmt and OpsJan 12Sale45.0011,000495,00024,701Jan 17 05:14 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJan 04Sale43.0115,000645,16842,801Jan 04 07:03 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJan 03Option Exercise4.5812,50157,25457,801Jan 04 07:03 PM
Rovaldi ChristopherSVP, Program Mgmt and OpsJan 03Sale42.4583335,36124,701Jan 04 07:05 PM
Sherman Matthew LEVP & Chief Medical OfficerJan 03Sale42.714,633197,86873,367Jan 04 07:02 PM
Rovaldi ChristopherSVP, Program Mgmt and OpsJan 02Sale42.411,43360,77425,534Jan 04 07:05 PM
Kumar RavindraSVP & Chief Scientific OfficerJan 02Sale42.414,300182,36392,675Jan 04 07:04 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJan 02Sale42.424,000169,68045,300Jan 04 07:03 PM
Quisel John DSVP, Corp. Dev., GC & Sec.Jan 02Sale42.424,333183,80652,977Jan 04 07:03 PM
George JeanDirectorDec 15Sale35.73105,1223,756,0090Dec 18 04:53 PM
Kumar RavindraSVP & Chief Scientific OfficerSep 28Option Exercise5.286,76135,69896,975Sep 29 04:13 PM
CELGENE CORP /DE/10% OwnerSep 25Buy37.00745,59227,586,9046,118,479Sep 25 04:23 PM